CIAO3: A Potential Drug Target and Biomarker for the Protein Related to Narf

Target Name: CIAO3

NCBI ID: G64428

CIAO3

CIAO3: A Potential Drug Target and Biomarker for the Protein Related to Narf

Narf (NAD+-dependent RNA binding protein) is a key regulator of gene expression and has been implicated in various cellular processes, including DNA replication, transcription, and post-transcriptional modification. The protein related to Narf (CIAO3) has been identified and its function is under investigation. This article will review the literature on CIAO3, its potential drug targets, and its potential as a biomarker for various diseases.

Potential Drug Targets

CIAO3 is a 21-kDa protein that is expressed in various tissues and has been shown to play a role in regulating gene expression. Several studies have identified potential drug targets for CIAO3.

1. Nuclear export
CIAO3 is a nuclear export protein, which means it can transport proteins from the nucleus to the cytoplasm. The nuclear export of CIAO3 has been implicated in the regulation of various cellular processes, including cell growth, apoptosis, and inflammation. Therefore, inhibitors of CIAO3 nuclear export may be potential drugs for various diseases, such as cancer, neurodegenerative diseases, and autoimmune diseases.
2. mTOR signaling
CIAO3 has been shown to be involved in the mTOR signaling pathway, which is a key regulator of cellular processes that are involved in cell growth, metabolism, and stress responses. Therefore, inhibitors of CIAO3 may be potential drugs for diseases that are characterized by mTOR signaling pathway dysfunction, such as obesity, type 2 diabetes, and neurodegenerative diseases.
3. NF-kappa-B signaling
CIAO3 has been shown to be involved in the NF-kappa-B signaling pathway, which is involved in inflammation and cellular stress responses. Therefore, inhibitors of CIAO3 may be potential drugs for diseases that are characterized by inflammation or cellular stress responses, such as rheumatoid arthritis, colitis, and cancer.

Potential Biomarkers

CIAO3 has also been shown to be involved in various signaling pathways and has been used as a potential biomarker for various diseases.

1. Cancer
CIAO3 has been shown to be involved in the regulation of cell cycle progression and has been used as a potential biomarker for cancer. Several studies have shown that CIAO3 expression is increased in various types of cancer, including breast, lung, and colorectal cancer. Therefore, inhibitors of CIAO3 may be potential drugs for cancer.
2. Neurodegenerative diseases
CIAO3 has been shown to be involved in the regulation of neurotransmitter synthesis and release, which is important for the function of neurons in neurodegenerative diseases. Therefore, changes in CIAO3 expression levels may be a potential biomarker for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.
3. Inflammatory diseases
CIAO3 has been shown to be involved in the regulation of inflammation and cellular stress responses, which are important for the development and progression of inflammatory diseases. Therefore, changes in CIAO3 expression levels may be a potential biomarker for inflammatory diseases, such as rheumatoid arthritis and colitis.

Conclusion

CIAO3 is a protein that has been shown to play a role in regulating various cellular processes and has been identified as a potential drug target and biomarker for various diseases. Further research is needed to fully understand the function of CIAO3 and its potential as a drug and biomarker.

Protein Name: Cytosolic Iron-sulfur Assembly Component 3

Functions: Component of the cytosolic iron-sulfur protein assembly (CIA) complex, a multiprotein complex that mediates the incorporation of iron-sulfur cluster into extramitochondrial Fe/S proteins. Seems to negatively regulate the level of HIF1A expression, although this effect could be indirect

The "CIAO3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CIAO3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets